Intra-articular Botulinum Toxin Type A Versus Corticosteroids: a Clinical Trial in Osteoarthritis of Knees
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 105
- 试验地点
- 1
- 主要终点
- Changes on Pain
研究概览
简要总结
Introduction: Osteoarthritis of the knee is a very common disease. However there are few treatment options for these patients. Botulinum toxin type A is an option for chronic pain. If the investigators prove effectiveness of its use for intra-articular analgesia, Botulinum toxin type A can be useful for treat these patients.
Objective: Compare the effectiveness of the use of intra-articular corticosteroid versus Botulinum toxin type A in the treatment of patients with knee osteoarthritis.
Methods: A prospective controlled randomized double blind studied with three groups (n = 35 each group) of patients with symptomatic osteoarthritis of the knees receive intra-articular medication in a single moment will be undertaken. The three groups will be: Botulinum toxin type A Group: patients who receive 100 units of botulinum toxin; hexacetonide of triamcinolone Group: patients who receive 40mg of triamcinolone hexacetonide, and saline group: patients who receive 2ml of normal saline. Patients will be assessed by evaluators " blind " in 4 times during 12 weeks of follow-up with clinical assessment instruments (pain, quality of life questionnaire as short form 36 questionnaire) , functional ( WOMAC questionnaire) , and ultrasound (quantitative and semi quantitative measure of synovial hypertrophy and semi quantitative Power Doppler ) .The following statistical tests will be used : Student's t test, Mann - Whitney , chi- square test and ANOVA for repeated measures . Will be considered as statistical significance the difference of 5 %.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age above 50 years
- •diagnose of knee osteoarthritis using clinics and radiographic criteria
- •pain for more than 6 months
- •analogic visual scale among 4 to 8
- •patients who agree to sign informed consent
排除标准
- •secondary osteoarthritis
- •skin lesion
- •use of intraarticular corticosteroid in the last 3 months
- •use of oral corticosteroid in the last 30 days
- •Kellgren Lawrence I or IV
- •inflammatory arthritis
- •neuromuscular disease
- •use of aminoglycoside antibiotics
- •metalic prosthesis in knee
- •peripheric neuropathy
- •serious cardiovascular or pulmonary disease
- •serious disorder of coagulation
- •pregnancy or breastfeeding
- •infections
- •use of wheelchair
研究组 & 干预措施
Botulinum toxin group
Patients will receive a intervention with joint injection of 100 units of botulinum toxin
干预措施: Botulinum Toxin Type A (Drug)
Corticosteroid group
Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)
干预措施: Triamcinolone hexacetonide (Drug)
Saline Group
Patients will receive a joint injection of 2ml of normal saline
干预措施: Saline (Drug)
结局指标
主要结局
Changes on Pain
时间窗: Baseline, after 4, 8 and 12 weeks
Evaluated using the visual analogue scale
次要结局
- Changes on Ultrasound parameters(Baseline, after 4, 8 and 12 weeks)
- Changes on quality of life(Baseline, after 4, 8 and 12 weeks)
- Changes on function(Baseline, after 4, 8 and 12 weeks)
研究者
Jamille Godoy Mendes
MD
Federal University of São Paulo
